Skip to content

VIP - Vascular Infection Project

VIP - Vascular Infection Project : Prospective Multicentric Database on Vascular Infections

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06866535
Acronym
Cohorte VIP
Enrollment
1000
Registered
2025-03-10
Start date
2022-05-10
Completion date
2032-05-10
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortitis, Blood Vessel Prosthesis, Infections, Vascular Graft Infection

Keywords

vascular graft and endograft infections, infectious aortitis, infectious arteritis

Brief summary

Constitution of a prospective multicentric observational database to study vascular infections, both native, especially aortitis, and vascular graft and endograft infections. Clinical and paraclinical data on medical, surgical, anesthetic and intensive care management will be collected in order to better characterize these infections

Detailed description

Vascular infections are rare but severe, burdened by high morbi-mortality and recurrence rates. However, many questions remain regarding their management which is still not consensual, both surgical and medical management. The term vascular infections encompasses vascular graft and endograft infections, as well as infections of native arteries and the aorta. For vascular graft infections, the optimal surgery is to remove the infected graft before vascular reconstruction with a new graft, either synthetic or biologic. However, some patients are too fragile to undergo surgery and might then benefit from an endovascular graft, an abscess drainage or no surgery at all, only medical treatment. For native arterial infections, surgery is often required to remove the infected arterial wall before vascular reconstruction. However, some patients cannot be operated on and might also benefit from an endovascular surgery. In these two vascular infections, the ideal anti-microbial treatment is uncertain, whether it pertains to the duration of therapy, the type of molecules, or their number. All of these medical and surgical factors may impact the prognosis of patients and should be collectively assessed in order to determine the best strategy for enhancing their outcomes.

Interventions

None listed

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years-old; * all patients with a vascular infection, either native (aortitis, arteritis) or prosthetic (vascular graft, endograft and/or stent), * oral consent

Exclusion criteria

* patient under legal protection

Design outcomes

Primary

MeasureTime frameDescription
mortalityYear 1mortality r

Secondary

MeasureTime frameDescription
mortalityDay 30, Year 2, Year 5mortality rate
morbidityYear 1morbidity rate
relapseyear 1, Year 2, Year 5relapse rates
reinfectionyear 1, Year 2, Year 5reinfection rates

Countries

France

Contacts

Primary ContactMathilde Puges, MD
mathilde.puges@chu-bordeaux.fr+335 56 79 55 36

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026